1. Kuharchuk V. V., Konovalov G. A., Galjavich A. S. et al. Diagnostics and correction of dyslipidaemias in the prevention and treatment of atherosclerosis. Russian recommendations. Revision V. Ateroskleroz i dislipidemii 2012;4:5-61. Russian (Кухарчук В. В., Коновалов Г. А., Галявич А. С. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. V пересмотр. Атеросклероз и дислипидемии 2012;4:5-61).
2. Catapano A. L., De Backer G., Wiklund O. et al. ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. Advance Access published August 27, 2016. doi:10.1093/eurheartj/ehw272. http://eurheartj.oxfordjournals.org/content/early/ 2016/08/26/eur-heartj.ehw272.
3. Stone N.J., RobinsonJ. G., Lichtenstein A. H. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129: S1 - S45. doi: 10.1161/01.cir.0000437738.63853.7a.
4. Cholesterol Treatment Trialists' (CTT) Collaboration. Baigent C., Blackwell L., Emberson J. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81. doi: 10.1016/S0140-6736 (10) 61350-5.
5. King D. S., Wilburn A. J., Wofford M. R. et al. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 2003;23 (12):1663-1667.
6. Parker B. A., Polk D. M., Rabdiya V. et al. Changes in memory function and neuronal activation associated with atorvastatin therapy. Pharmacotherapy 2010;30 (6):236e - 40e.
7. US Food and Drug Administration. FDA Drug Safety Communication: Important safety label changes to cholesterollowering statin drugs 2012. http://www.fda.gov/Drugs/DrugSafe ty / ucm293101.htm.
8. Brass L. M., Alberts M.J., Sparks L. An assessment of statin safety by neurologists. Am J Cardiol 2006;97 (8A): 86С-88С. DOI: 10.1016/j.amjcard.2005.12.017
9. Bettermann K., Arnold A. M., Williamson J. et al. Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study. J Stroke Cerebrovasc Dis 2011; 21 (6):436-444. doi: 10.1016/j.jstrokecerebrovasdis.2010.11.002.
10. Muldoon M. F., Rossouw J. E., Manuck S. B., et al. Low or lowered cholesterol and risk of death from suicide and trauma. Metabolism 1993;42:45-56.
11. You H., Lu W., Zhao S. et al. TTe relationship between statins and depression: a review of the literature. Expert Opin Pharmacother 2013;14:1467-1476. doi: 10.1517/14656566.2013.803067.
12. O'Neil A., Sanna L., Redlich C., et al. The impact of statins on psychological wellbeing: a systematic review and meta-analysis. BMC Med 2012;10:154. doi: 10.1186/1741-7015-10-154.
13. While A., Keen L. TTe effects of statins on mood: a review of the literature. Eur J Cardiovasc Nurs 2012;11:85-96. doi: 10.1016/ j.ejcnurse.2010.08.008.
14. Golomb B. A., Evans M. A., Dimsdale J. E., et al. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med 2012;172:1180-1182. doi: 10.1001 /archinternmed.2012.2171.
15. Mikus C. R., Boyle L. J., Borengasser S. J., et al. Simvastatin impairs exercise training adaptation. J Am Coll Cardiol 2013;62:709-714. doi: 10.1016/j.jacc.2013.02.074.
16. http://newpsyhelp.ru/files/MoCA/MoCA.pdf
17. Инструкция по обработке данных, полученных с помощью опросника SF-36. http://therapy.irkutsk.ru/doc/sf36a.pdf
18. Permission for questionnaire SF-36 use. OPTUMINSIGHT NON-COMMERCIAL LICENSE. Lic.№: SLA QM0380024-CT183072-OP057524. https://campaign.optum.com/ content/optum/en.html
19. Orsi A., Sherman O., Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy 2001;21 (6):767-769.
20. Ott B. R., Daiello L. A., Dahabreh I.J. et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med 2015;30 (3):348-358. doi: 10.1007/s11606-014-3115-3.
21. Beydoun M. A., Beason-Held L. L., Kitner-Triolo M. H. et al. Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment. J Epidemiol Community Health 2011;65 (11):949-957. doi: 10.1136/jech.2009.100826.
22. Trompet S., van Vliet P., de Craen A.J. et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol 2010;257 (1):85-90. doi: 10.1007/s00415-009-5271-7.
23. Summers M.J., Oliver K. R., Coombes J. S. et al. Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial. Pharmacotherapy 2007;27 (2):183-190.10.1592/phco.27.2.183
24. Macedo A. F., Taylor F. C., Casas J. P. et al. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med 2014;12 (1):51. doi: 10.1186/1741-7015-12-51.
25. Rojas-Fernandes C. H., Goldstein L. B., Levey A. I. et al. An assessment by the Statin Cognitive Safety Task Force: 2014 update. J Clin Lipidol 2014;8: S5 - S16. doi: 10.1016/j.jacl.2014.02.013.
26. Swiger K.J., Manalac R.J., Blumenthal R. S. et al. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc 2013;88 (11):1213-1221. doi: 10.1016/j.mayocp.2013.07.013.
27. Okifuji A., Hare B. D. The association between chronic pain and obesity. J Pain Res 2015;8:399-408. doi: 10.2147/JPR.S55598.
